Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors ; volume:25 ; number:6 ; day:2 ; month:5 ; year:2024 ; pages:719-751 ; date:6.2024
Current treatment options in oncology ; 25, Heft 6 (2.5.2024), 719-751, 6.2024
- Creator
-
Tecik, Melisa
Adan, Aysun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-024-01202-7
- URN
-
urn:nbn:de:101:1-2409231204015.377389722624
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tecik, Melisa
- Adan, Aysun
- SpringerLink (Online service)
Other Objects (12)
FLT3-ITD regulated miRs in AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Identification of Protein Tyrosine Phosphatases regulating FLT3 activity and of PTPs regulated by FLT3 ITD
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Role of FLT3 ITD PTPRC signaling in bone remodeling
The role of STAT5 in FLT3-ITD-mediated leukemogenesis
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
FLT3-ITD regulated miRs in AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Identification of Protein Tyrosine Phosphatases regulating FLT3 activity and of PTPs regulated by FLT3 ITD
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Role of FLT3 ITD PTPRC signaling in bone remodeling
The role of STAT5 in FLT3-ITD-mediated leukemogenesis
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien
Dendritic Cell dysfunctions in AML patients with FLT3 ITD mutations
FLT3-ITD regulated miRs in AML
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Identification of Protein Tyrosine Phosphatases regulating FLT3 activity and of PTPs regulated by FLT3 ITD
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
Role of FLT3 ITD PTPRC signaling in bone remodeling
The role of STAT5 in FLT3-ITD-mediated leukemogenesis
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML
Dendritic cell dysfunctions in AML patients with FLT3 ITD mutations
Effekte von FLT3-ITD Inhibitoren auf Chemotherapie resistente AML Zelllinien